FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
AACR approaches, along with ASCO abstract titles.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.